Grauer K, Cavallaro D, Gums J
University of Florida College of Medicine, Gainesville.
Am Fam Physician. 1991 Mar;43(3):832-44.
Since the last revision of the American Heart Association's guidelines in 1985, several new developments of clinical importance have occurred in the field of cardiopulmonary resuscitation. These include enhanced access to and earlier use of defibrillation, the use of high-dose epinephrine when standard doses fail, the assessment of resuscitative efforts with end-tidal CO2 monitoring and the addition of two new drugs, amiodarone (for refractory ventricular fibrillation) and adenosine (for paroxysmal supraventricular tachycardia). Time will determine the ultimate role of these advancements in the management of cardiac arrest.
自1985年美国心脏协会指南上次修订以来，心肺复苏领域出现了几项具有临床重要意义的新进展。这些进展包括更容易获得和更早使用除颤、在标准剂量无效时使用大剂量肾上腺素、通过呼气末二氧化碳监测评估复苏效果以及增加了两种新药，即胺碘酮（用于难治性室颤）和腺苷（用于阵发性室上性心动过速）。时间将决定这些进展在心脏骤停管理中的最终作用。
